Dr. Amy Egan

• 
  www.risas.org/poc/view_doc.php?type=news&id=123393&cn=2 - [Cached Version]
  Published on: 11/4/2009    Last Visited: 11/4/2009  

  "Health care professionals and patients taking Byetta should pay close attention to any signs or symptoms of kidney problems," Amy Egan, M.D., of the Division of Metabolism and Endocrinology Products at the FDA's Center for Drug Evaluation and Research in Silver Spring, Md., said in a statement.

• 
  www.forecast.diabetes.org/news/fda-warns-against-sharin - [Cached Version]
  Published on: 3/19/2009    Last Visited: 9/3/2009  

  "Insulin pens are designed to be safe for one patient to use one pen multiple times with a new, fresh needle for each injection," said Dr. Amy Egan, deputy director of safety at the FDA's division of metabolism and endocrinology products.

• 
  truckmakegreen.blogrevo.com/2008/05/17/she-noted-percen - [Cached Version]
  Last Visited: 5/21/2008  

  Amy Egan, a FDA medical officer told federal health advisers.Even if the FDA does approve the first in its class drug, the findings make it highly likely it would bear stern warnings.
  
  She noted percent of those reporting psychiatric problems while on the drug had no prior history of depression.

• 
  www.pharmpro.com/ShowPR~PUBCODE~021~ACCT~0000100~ISSUE~ - [Cached Version]
  Published on: 6/4/2009    Last Visited: 6/4/2009  

  "After analyzing adverse event reports, the FDA has identified an increased risk of liver injury with propylthiouracil when compared to an alternative treatment for Graves' disease, methimazole," said Amy Egan, M.D., deputy director for safety, Division of Metabolism and Endocrinology Products, in the FDA’s Center for Drug Evaluation and Research.

• 
  health.discovery.com/news/healthscout/article.html?arti - [Cached Version]
  Published on: 11/3/2009    Last Visited: 11/4/2009  

  "Health care professionals and patients taking Byetta should pay close attention to any signs or symptoms of kidney problems," said Dr. Amy Egan, of the Division of Metabolism and Endocrinology Products at the FDA's Center for Drug Evaluation and Research.

• 
  health.discovery.com/news/healthscout/article.html?arti - [Cached Version]
  Published on: 11/2/2009    Last Visited: 11/3/2009  

  "Health care professionals and patients taking Byetta should pay close attention to any signs or symptoms of kidney problems," said Dr. Amy Egan, of the Division of Metabolism and Endocrinology Products at the FDA's Center for Drug Evaluation and Research.

• 
  www.baptistphysicianslexington.com/News/Health+News?art - [Cached Version]
  Published on: 11/2/2009    Last Visited: 11/4/2009  

  "Health-care professionals and patients taking Byetta should pay close attention to any signs or symptoms of kidney problems," Dr. Amy Egan, of the Division of Metabolism and Endocrinology Products at the FDA's Center for Drug Evaluation and Research, said in an FDA news release.
  
  "Patients also should be aware that problems with kidney function could lead to changes in urine color, frequency of urination or the amount of urine, unexplained swelling of the hands or feet, fatigue, changes in appetite or digestion, or dull ache in the mid- to lower back," Egan said.
  
  She advised patients with any of these symptoms to immediately consult with a health-care professional.

• 
  www.sciam.com/article.cfm?alias=panel-rejects-sanofi-ob - [Cached Version]
  Published on: 9/20/2006    Last Visited: 6/14/2007  

  "The potential market for this drug and our continued uncertainty about its risks, both known and unknown, lead to our concern" about use in the general population, said FDA medical officer Amy Egan.

• 
  www.kuwaitpharmacy.com/newsDetail.aspx?ID=989 - [Cached Version]
  Published on: 6/3/2009    Last Visited: 6/13/2009  

  "After analyzing adverse event reports, the FDA has identified an increased risk of liver injury with propylthiouracil when compared to an alternative treatment for Graves' disease, methimazole," said Amy Egan, M.D., deputy director for safety, Division of Metabolism and Endocrinology Products, in the FDA's Center for Drug Evaluation and Research.

• 
  www.upi.com/Science_News/2009/06/03/UPI-NewsTrack-Healt - [Cached Version]
  Published on: 6/3/2009    Last Visited: 6/4/2009  

  "After analyzing adverse event reports, the FDA has identified an increased risk of liver injury with propylthiouracil (commonly known as PTU) when compared to an alternative treatment for Graves' disease, methimazole," Dr. Amy Egan of the FDA's Center for Drug Evaluation and Research said.

Page:  1 2 3 4